Ring Sulfur In The Polycyclo Ring System Patents (Class 514/324)
-
Publication number: 20140113936Abstract: The methods disclosed herein relate to the treatment of skin infections in dogs, by-administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against Malassezia sp. is described.Type: ApplicationFiled: September 12, 2013Publication date: April 24, 2014Applicant: BRIDGE PHARMA, INC.Inventors: A.K. Gunnar Aberg, Vincent B. Ciofalo
-
Publication number: 20140105957Abstract: The present invention relates to an ocular polymer delivery composition comprising at least one ophthalmologic agent dispersed in at least one biodegradable polymer, wherein the polymer comprises at least one of a poly (ester amide) (PEA) having a chemical formula described by structural formula (I).Type: ApplicationFiled: May 2, 2012Publication date: April 17, 2014Applicant: DSM IP ASSETS B.V.Inventors: Astrid Franken, George Mihov, Jens Christoph Thies
-
Publication number: 20140107085Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.Type: ApplicationFiled: October 10, 2013Publication date: April 17, 2014Applicant: The Trustees of The University of PennsylvaniaInventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
-
Publication number: 20140072571Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.Type: ApplicationFiled: March 11, 2013Publication date: March 13, 2014Applicant: TETHYS BIOSCIENCE, INC.Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
-
Publication number: 20140066451Abstract: The claimed subject matter is directed to certain thioxanthene derivatives and phenothiazine derivatives suitable for use as anti-infective agents, in particular, for the treatment of infectious diseases. The claimed subject matter furthermore relates to compositions including said anti-infective agents.Type: ApplicationFiled: November 4, 2013Publication date: March 6, 2014Applicant: BKG PHARMA APSInventor: Birgit Kjaeldgaard GIWERCMAN
-
Publication number: 20140011774Abstract: This invention provides pharmaceutical compositions comprising combination of SARM compounds and antiresorptive agents such as SERM compounds, including, inter-alia, Raloxifene, and uses thereof for treating osteoporosis and associated diseases.Type: ApplicationFiled: March 13, 2013Publication date: January 9, 2014Inventors: James T. DALTON, Duane D. Miller, Juhyun Kim, Mitchell S. Steiner
-
Publication number: 20140011843Abstract: Ophthalmic compositions and methods of preparing such compositions are disclosed.Type: ApplicationFiled: May 15, 2013Publication date: January 9, 2014Applicant: Johnson & Johnson Vision Care, Inc.Inventors: Shivkumar Mahadevan, Frank Molock, Vandeeta Khanolkar
-
Patent number: 8618303Abstract: The invention provides compounds of formula wherein R1, R2, R3, R4, R5, and R6 are as defined herein or a pharmaceutically suitable acid addition salt thereof. The present compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).Type: GrantFiled: January 2, 2012Date of Patent: December 31, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Henner Knust, Matthias Nettekoven, Hasane Ratni, Walter Vifian
-
Publication number: 20130345259Abstract: A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae.Type: ApplicationFiled: April 29, 2010Publication date: December 26, 2013Inventors: Claudio Bucolo, Keith W. Ward, Jinzhong Zhang
-
Publication number: 20130345150Abstract: An ophthalmic composition comprising a polyaphron dispersion.Type: ApplicationFiled: March 14, 2012Publication date: December 26, 2013Inventor: Fraser Steele
-
Patent number: 8614328Abstract: Provided are 4?-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.Type: GrantFiled: March 1, 2012Date of Patent: December 24, 2013Assignee: Celgene CorporationInventors: Alexander L. Ruchelman, George W. Muller, Hon-Wah Man, Roger Shen-Chu Chen
-
Publication number: 20130338106Abstract: Disclosed are compounds of Formula I: and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO2—, —O— or NRa-, and Ra, and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.Type: ApplicationFiled: February 23, 2012Publication date: December 19, 2013Inventors: John A. McCauley, Thomas J. Greshock, John Sanders, Heather H. Stevenson, Jonathan T. Kern, Ronald K. Chang
-
Patent number: 8604059Abstract: The claimed subject matter is directed to certain thioxanthene derivatives and phenothiazine derivatives suitable for use as anti-infective agents, in particular, for the treatment of infectious diseases. The claimed subject matter furthermore relates to compositions including said anti-infective agents.Type: GrantFiled: April 20, 2010Date of Patent: December 10, 2013Assignee: BKG Pharma APSInventor: Birgit Kjældgaard Giwercman
-
Publication number: 20130324507Abstract: The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.Type: ApplicationFiled: June 5, 2013Publication date: December 5, 2013Applicant: BIOPROJETInventors: Isabelle BERREBI-BERTRAND, Xavier BILLOT, Thierry CALMELS, Marc CAPET, Stéphane KRIEF, Olivier LABEEUW, Jeanne-Marie LECOMTE, Nicolas LEVOIN, Xavier LIGNEAU
-
Patent number: 8597666Abstract: A pharmaceutical formulation of compounds with low aqueous solubility and method of manufacture thereof. The formulation may include a pharmacologically active compound having low aqueous solubility and starch in the amount of greater than about 25 weight percent. A manufacturing method may include blending the active compound and starch, compressing the blend into a solid, comminuting the solid into granules, wetting the granules, drying the granules, and tabletting the dried granules to make a solid pharmaceutical formulation.Type: GrantFiled: October 28, 2011Date of Patent: December 3, 2013Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Ilan Zalit, Fanny Leska, Mali Kadosh, Dorit Marco, Yonit Messer-Triger
-
Patent number: 8580965Abstract: Substituted sulfonamide compounds with bradykinin receptor (B1R) modulating activity; processes for the preparation thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or inhibit pain and/or other disorders and/or disease states.Type: GrantFiled: October 16, 2007Date of Patent: November 12, 2013Assignee: Gruenenthal GmbHInventors: Stefan Oberboersch, Melanie Reich, Stefan Schunk, Sabine Hees, Ruth Jostock, Michael Engels, Achim Kless, Thomas Christoph, Klaus Schiene, Tieno Germann, Edward Bijsterveld
-
Publication number: 20130295202Abstract: Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient.Type: ApplicationFiled: July 3, 2013Publication date: November 7, 2013Inventor: John G. Stark
-
Patent number: 8557846Abstract: The methods disclosed herein relate to the treatment of dermal disorders, such as for example atopic dermatitis, in dogs, by administering a therapeutically effective amount of racemic norketotifen. Co-administrations with steroids or immunosuppressant drugs are described.Type: GrantFiled: January 11, 2013Date of Patent: October 15, 2013Assignee: Bridge Pharma, Inc.Inventors: A. K. Gunnar Aberg, Vincent B. Ciofalo
-
Publication number: 20130261130Abstract: The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is —CON—R3R4, —NR5COR6, —NHR7, —OR8, —SR9, —CH2NR10R11, —(CH2)2-R12, —CH?CH—R12, —C?C—R12, optionally substituted phenyl, optionally substituted thiophenyl, or optionally substituted 1,2,3-triazol-4-yl, W is hydrogen, hydroxy or carboxymethoxy, Y is carboxy, methoxycarbonyl or 2H-tetrazol-5-yl, and the various substituents R have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers.Type: ApplicationFiled: October 31, 2011Publication date: October 3, 2013Inventors: Shaheen Ahmed, Stefan Hettwer, Jan Willem Vrijbloed, Carlo Farina, Hans Allgeier
-
Patent number: 8536342Abstract: Disclosed is a process for producing a thiabenzoazulene-propionic acid derivative which is useful as an active ingredient of an antihistaminic agent or the like. According to the producing process of the present invention, it is possible to produce a thiabenzoazulene-propionic acid derivative where the 2-position of the thiabenzoazulene skeleton is substituted with propionic acid. The thiabenzoazulene propionic-acid derivative thus synthesized has excellent antagonistic action to histamine H1 receptor and low intracerebral transmigration and, therefore, is useful as an active ingredient of the pharmaceutical composition such as an antihistaminic agent.Type: GrantFiled: July 26, 2010Date of Patent: September 17, 2013Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Kunihiko Higashiura, Taizo Ito, Takashi Ogino, Taisuke Hasegawa
-
Publication number: 20130237547Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein Y, R1, R2, R3, R4, RA, and RB are defined herein.Type: ApplicationFiled: March 28, 2013Publication date: September 12, 2013Applicant: Janssen Pharmaceutica, NVInventor: Jay M. Matthews
-
Publication number: 20130231362Abstract: The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity.Type: ApplicationFiled: April 15, 2013Publication date: September 5, 2013Applicant: The Brigham and Women's Hospital, IncInventor: Guo-Ping Shi
-
Publication number: 20130217620Abstract: The present invention relates to ionic silicone hydrogel contact lenses which comprise at least one pharmaceutical or nutriceutical component and are formed from reaction mixtures comprising a mixture of slow-reacting hydrophilic monomers, including at least one slow-reacting ionic monomer, at least one silicone-containing component and at least one hydroxyl-containing component, wherein the ratio of the slow-reacting hydrophilic component half lives to the silicone-containing component half life is at least 2.Type: ApplicationFiled: March 14, 2013Publication date: August 22, 2013Applicant: Johnson & Johnson Vision Care, Inc.Inventor: Johnson & Johnson Vision Care, Inc.
-
Patent number: 8513285Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder.Type: GrantFiled: January 19, 2012Date of Patent: August 20, 2013Assignee: SK Biopharmaceuticals Co., Ltd.Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyan Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
-
Publication number: 20130203813Abstract: The present invention relates to ionic silicone hydrogel polymers comprising at least one pharmaceutical or nutriceutical component and displaying improved lysozyme uptake, low contact angle and reduced water soluble polymeric ammonium salt uptake.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: Johnson & Johnson Vision Care, Inc.Inventor: Johnson & Johnson Vision Care, Inc.
-
Publication number: 20130203812Abstract: The present invention relates to ionic silicone hydrogel polymers displaying improved thermal stability. More specifically, the present invention relates to a polymer formed from reactive components comprising at least one silicone component and at least one ionic component comprising at least one anionic group. The polymers of the present invention display good thermal stability and desirable protein uptake.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: Johnson & Johnson Vision Care, Inc.Inventor: Johnson & Johnson Vision Care, Inc.
-
Publication number: 20130177609Abstract: An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective.Type: ApplicationFiled: February 27, 2013Publication date: July 11, 2013Inventor: Bausch & Lomb Incorporated
-
Patent number: 8481572Abstract: Provided is a pharmaceutical composition including as an active component a compound of formula (I): wherein X and (R1)n are as defined, and a physiological acceptable carrier. Also provided is a method for treating cancer including administering to an individual in need of such treatment an effective amount of the presently described pharmaceutical composition.Type: GrantFiled: August 10, 2008Date of Patent: July 9, 2013Assignee: Urifer Ltd.Inventors: Uri Nir, Sally Shpungin, Etai Yaffe, Moshe Cohen
-
Publication number: 20130172256Abstract: The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing.Type: ApplicationFiled: December 28, 2011Publication date: July 4, 2013Applicant: KUWAIT UNIVERSITYInventors: FAHD AL-MULLA, MILAD S. BITAR
-
Publication number: 20130165480Abstract: Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.Type: ApplicationFiled: January 11, 2013Publication date: June 27, 2013Applicant: Novartis AGInventor: Novartis AG
-
Publication number: 20130165422Abstract: The disclosure relates to hexafluoroisopropyl carbamate derivatives of general formula (I): in which: R, Z, A, m, and n are as defined in the disclosure; in the form of the base or of an addition salt with an acid, and to the preparation process and therapeutic application thereof.Type: ApplicationFiled: November 29, 2012Publication date: June 27, 2013Applicant: SANOFIInventor: SANOFI
-
Patent number: 8466174Abstract: Ophthalmic compositions and methods of preparing such compositions are disclosed.Type: GrantFiled: March 16, 2007Date of Patent: June 18, 2013Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Shivkumar Mahadevan, Frank Molock, Vandeeta Khanolkar
-
Publication number: 20130142730Abstract: The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.Type: ApplicationFiled: November 14, 2012Publication date: June 6, 2013Applicant: ZIOPHARM ONCOLOGY, INC.Inventor: ZIOPHARM Oncology, Inc.
-
Patent number: 8445435Abstract: The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity.Type: GrantFiled: September 24, 2008Date of Patent: May 21, 2013Assignee: The Brigham and Women's Hospital, Inc.Inventor: Guo-Ping Shi
-
Publication number: 20130102634Abstract: Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein.Type: ApplicationFiled: November 9, 2012Publication date: April 25, 2013Inventor: Novartis AG
-
Publication number: 20130053369Abstract: The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. A tetrahydrobenzothiophene compound of the following formula (I) has NPT-IIb inhibitory action and can be used as an agent for treating and/or preventing hyperphosphatemia: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form 5- to 7-membered saturated cyclic amino; R4's are the same as or different from each other and represent halogen, lower alkyl; and n represents 0 to 2.Type: ApplicationFiled: October 26, 2012Publication date: February 28, 2013Applicant: Astellas Pharma Inc.Inventor: Astellas Pharma Inc.
-
Patent number: 8377967Abstract: The present invention provides a compound a piperidine derivative having excellent histamine receptor antagonistic action, which is useful as active ingredients of a pharmaceutical composition, especially an antihistamine. The piperidine derivative of the present invention has a potent histamine receptor antagonistic action. Further, the compound of the present invention shows low brain transfer even in a cerebral receptor binding test where a mouse is orally administered with the compound, so that the compound has preferred properties of alleviating side effects in the central nervous system, such as drowsiness. The piperidine derivative of the present invention is very useful as a novel antihistamine having smaller side effects in the central nervous system, such as drowsiness.Type: GrantFiled: November 20, 2008Date of Patent: February 19, 2013Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Kunihiko Higashiura, Takashi Ogino, Taizo Ito, Hiroyuki Iwatsuki
-
Publication number: 20130029973Abstract: A compound has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating hyperphosphatemia, preventing hyperphosphatemia, or both. The compound is a tetrahydrobenzothiophene compound. A pharmaceutical composition for treating hyperphosphatemia includes the compound or salt thereof. A method of treating hyperphosphatemia includes administering to a subject an effective amount of the compound or salt thereof.Type: ApplicationFiled: April 27, 2011Publication date: January 31, 2013Applicant: ASTELLAS PHARMA INC.Inventors: Shunichiro Hachiya, Masanori Miura, Yoshimasa Imamura, Daisuke Kaga, Ippei Sato, Hiroyuki Moritomo, Koji Kato, Kazuhiro Terai, Yoh Terada
-
Publication number: 20130023520Abstract: An eye drop solution includes an anaesthetic and at least one medicament. The anaesthetic is preferably provided in a range of from about 0.001% to about 1.0%. The eye drop solution may further include either a lubricant or a preservative, or both of these.Type: ApplicationFiled: July 24, 2011Publication date: January 24, 2013Inventor: Amir Sahba Jalali
-
Patent number: 8350041Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.Type: GrantFiled: December 22, 2011Date of Patent: January 8, 2013Assignee: Janssen Pharmaceutica, NVInventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
-
Patent number: 8344149Abstract: Crystalline raloxifene hydrochloride in hydrated form, particularly the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and uses thereof.Type: GrantFiled: October 17, 2007Date of Patent: January 1, 2013Assignee: Cipla LimitedInventors: Srinivas Laxminarayan Pathi, Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao
-
Publication number: 20120302539Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.Type: ApplicationFiled: May 7, 2012Publication date: November 29, 2012Inventors: Michael Prime, Stephen Martin Courtney, Richard Marston, Celia Dominguez, Douglas Macdonald, John Wityak
-
Publication number: 20120302562Abstract: Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.Type: ApplicationFiled: May 23, 2012Publication date: November 29, 2012Inventors: Joseph BARBOSA, Kenneth Gordon CARSON, Michael Walter GARDYAN, Jason Patrick HEALY, Qiang HAN, Ross MABON, Praveen PABBA, James TARVER, JR., Kristen M. TERRANOVA, Ashok TUNOORI, Xiaolian XU
-
Publication number: 20120238567Abstract: The present invention relates to compounds having pharmacological activity towards the sigma (?) receptor, and more particularly to some 4, 5, 6, 7 tetrahydrobenzo[b]thiophene derivatives, wherein n is selected from 0, 1, 2, 3 or 4; m is selected from 0, 1 or 2; the dotted line represents either a single or a double bond; to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Applicant: LABORATORIOS DEL DR. ESTEVE, S.A.Inventors: Jordi CORBERA-ARJONA, Daniel MARTINEZ-OLMO, David VANO-DOMENECH
-
Publication number: 20120220558Abstract: The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, or tautomers thereof, in a regimen which involves delivering one or more of a selective estrogen receptor modulator, wherein formula I is: and wherein R1-R5 and Q1 are defined as described herein. Methods of providing hormone replacement therapy and for treating carcinomas, dysfunctional bleeding, uterine leiomyomata, endometriosis, and polycystic ovary syndrome is provided which includes delivering a compound of formula I and a selective estrogen receptor modulator are also described.Type: ApplicationFiled: May 8, 2012Publication date: August 30, 2012Applicant: Wyeth LLCInventors: Andrew Fensome, Gary S. Grubb, Diane Deborah Harrison, Richard Craig Winneker
-
Publication number: 20120207766Abstract: The present invention is directed to the identification of novel mechanisms involved in the initiation and spreading of axonal degeneration. In particular, the instant invention relates to the identification of a relationship between Toll-Like Receptors (TLRs) and axonal degeneration and the use of TLR inhibitors as antagonists of axonal degeneration.Type: ApplicationFiled: January 30, 2012Publication date: August 16, 2012Inventors: Athena Soulika, David Pleasure
-
Publication number: 20120201908Abstract: The disclosure provides methods of treating bipolar disorder by administering an antiestrogen to reduce the severity and frequency of mood episodes. The disclosure further provides methods of treating depression with an antiestrogen in a descending dose protocol.Type: ApplicationFiled: August 12, 2010Publication date: August 9, 2012Applicant: Lunera Equities, LLLPInventor: Kirk Patrick Miller
-
Publication number: 20120196882Abstract: The invention provides methods and compounds for the treatment and prevention of malaria infection and transmission in a mammal by administering compounds of the invention to a mammal having or suspected of having a malaria infection. The invention also provides pharmaceutical compositions that can kill or arrest the growth of Plasmodium organisms, and especially Plasmodium falciparum, thereby preventing or blocking transmission of malaria as well as treating malaria infection.Type: ApplicationFiled: August 27, 2010Publication date: August 2, 2012Inventors: Dipak Raj, Sittiporn Pattaradilokrat, Ron Johnson, Ruili Huang
-
Publication number: 20120178719Abstract: The present invention relates to methods of treating neurodegenerative diseases comprising administering, to a subject in need of such treatment, one or more agent that inhibits or reduces the action, including the catalytic activity, of an enzyme of the phospholipase D family, such as phospholipase D1 and/or phospholipase D2. The present invention also relates to cell-based assays which may be used to identify agents that inhibit or reduce the activity of enzymes of the phospholipase D family and that may be used in the treatment of neurodegenerative diseases.Type: ApplicationFiled: November 28, 2011Publication date: July 12, 2012Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Gilbert DiPaolo, Tae-Wan Kim, Tiago Gil Oliveira
-
Publication number: 20120178781Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.Type: ApplicationFiled: February 29, 2012Publication date: July 12, 2012Applicant: RESEARCH TRIANGLE INSTITUTEInventors: Frank Ivy CARROLL, Hernan A. Navarro, Lawrence E. Brieaddy, Scott P. Runyon, James B. Thomas